Fact checked byChristine Klimanskis, ELS

Read more

December 09, 2022
1 min read
Save

CORD submits premarket approval application for SC9 IOL

Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CORD has submitted a premarket approval application to the FDA for the Model SC9 IOL to treat patients with cataracts, according to a press release.

The lens was designed by J. Stuart Cumming, MD, FACS, FRCOphth, to provide intermediate vision superior to that of a standard monofocal IOL. It has a single-focus spherical optic and a rigid structure to locate the optic to provide intermediate vision.

FDA sign
CORD has submitted a premarket approval application to the FDA for the Model SC9 IOL to treat patients with cataracts, according to a press release.
Source: Adobe Stock.

The application is backed by the results of more than 300 patients who were followed for at least 1 year under an approved investigational device exemption, according to the release.

Cumming is also the designer of the Crystalens IOL, now owned by Bausch +Lomb, which was approved by the FDA in 2003.